● Business WireNov 10, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.…
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $90.00…
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.…
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Direc…
Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI an…
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to …
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.…
● Business WireNov 2, 2026 · 08:02 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.…
● Zacks Investment ResearchOct 27, 2026 · 11:06 ET
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…
● Business WireOct 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to…
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat reports. One a…
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare th…
● Zacks Investment ResearchOct 13, 2026 · 11:45 ET
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.…
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript…
Mirum Pharmaceuticals’ LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals (NASDAQ: MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associat…
● Business WireOct 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.…
● Business WireOct 11, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.…
● Business WireSep 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.…
Article counts from the last market-wide feed page, across every symbol we track and not just MIRM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.